featured
Enfortumab Vedotin-ejfv Improves OS Significantly in Previously Treated Locally Advanced or Metastatic Urothelial Cancer
The trial was stopped early due to positive results at interim analysis.
Sign in to PracticeUpdate
Only registered members have full access to PracticeUpdate content.
Additional Info
Disclosure statements are available on the authors' profiles: